"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"

NCT02058173 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: 150 mg/daily chloroquine compare to placebo for 12 week
DRUG: Chloroquine
DRUG: placebo

Sponsor

Shiraz University of Medical Sciences